Kinderer Baby Pharmaceuticals Co., Ltd. Established
Spike Pharmaceuticals Enters Infant Drug Market
Recently, the Sino-German joint venture Zhejiang Jinder Baby Drug Co., Ltd., which is controlled by Jianfeng Pharmaceutical, has completed its registration. Jianfeng Pharmaceutical will introduce German technology and products on this basis to open up the infant drug market.
Zhejiang Jinderer Baby Drug Co., Ltd. was jointly funded by Jianfeng Pharmaceutical, Germany Gefu Pharmaceutical Co., Ltd. and Zhuhai Hengqin Deyunjia International Trade Co., Ltd., with a registered capital of 20 million yuan, of which Jianfeng Pharmaceutical contributed 11 million yuan in cash, accounting for 55% of the registered capital. Gefu Pharmaceuticals invested 5 million yuan in the evaluation of two proprietary technologies of "diazepam suppository" and "acetaminophen suppository, 25% of the registered capital; De Yunjia contributed 4 million yuan in cash, accounting for 20% of the registered capital. The company's registered address is in Jinxi Development Zone, Jinhua City. It will rent the existing factory building of Jianfeng Pharmaceutical Jinxi Pharmaceutical Factory for renovation, and strive to absorb their respective expertise and adopt appropriate advanced technology and scientific management methods. A modern pharmaceutical enterprise focusing on the research and development, production and sales of pharmaceutical preparations for infants and children.
In this cooperation, the corresponding products of "diazepam suppository" and "acetaminophen suppository", which Ge Fu pharmaceutical has invested in with proprietary technology evaluation, have been listed in Germany, among which diazepam suppository is a therapeutic drug for anti-anxiety, sleep disorder and muscle tension increase; acetaminophen is used for fever caused by cold or cold, and also for relieving mild to moderate pain. After the establishment of the joint venture company, it will carry out research and development and operation of corresponding products on the basis of these two proprietary technologies.
With the adjustment of China's population policy and the implementation of the "comprehensive two-child" policy, it is expected that the infant drug market will usher in opportunities for rapid growth. This time, through the establishment of a joint venture company and the introduction of German technology to develop infant drugs, it is an important step for Jianfeng Pharmaceutical to take in response to market demand, and it is also the specific implementation of expanding and strengthening the pharmaceutical business according to the company's development strategic plan. (this newspaper reporter)
